Abstract
Generalized anxiety disorder (GAD) is a high-prevalence disorder with a relatively early age of onset. The disorder tends to be chronic, causes moderate levels of impairment in functioning and quality of life, and frequently is complicated by other Axis I and Axis II comorbid disorders. As a consequence, the focus of GAD treatment should be on long-term management strategies. This article summarizes available data on the longitudinal course of GAD, and provides a critical review of issues important to the long-term pharmacologic treatment of the disorder.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
